Skip to main content

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

Active, not recruiting · Phase 3 · NCT03398135

Conditions: Ulcerative Colitis (UC)

At a glance

Research payments reported, 2025
$463,246
U.S. investigators named
36
Sites paid
36
Planned or actual enrollment
1,242

About the trial

Sponsor
AbbVie
Tested
risankizumab (drug), placebo for risankizumab (drug)
Dates
Started 2018-08-28; completion 2029-02
Results posted
Not yet

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC. This study consists of three sub-studies and a Continuous Treatment Extension (CTE): Substudy 1 is a 52-week, randomized, double-blind, placebo-controlled maintenance study; Substudy 2 is 52-week, randomized, exploratory maintenance study; and Substudy 3 is an open-label long-term extension study for participants who completed Substudy 1 or 2, or participants who responded to induction treatment in Study M16-067 with no final endoscopy due to the Covid-…

From ClinicalTrials.gov, last updated 2026-01-20. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $463,246 in research payments for this study in 2025 (158 payments).

Products named: Skyrizi

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Cedars-Sinai Medical Center, CA $45,954
  • Gastroenterology Associates Of $38,126
  • Mayo Clinic Rochester $30,015
  • Southern California Research Center $28,994
  • Southern Star Research $27,395
  • Benaroya Research Institute $26,086
  • Avicenna Clinical Research LLC $25,639
  • Endoscopic Research Inc $21,856
  • Clinical Associates in Research $19,613
  • Louisiana Research Center LLC $19,527
  • Gastroenterology Center of the Midsouth PLLC DBA Gastro One $17,339
  • University of Kansas Medical Center $16,699
  • Vanderbilt University Medical Center, TN $16,435
  • Texas Digestive Disease $16,113
  • Medical Research Center of Connecticut $13,886
  • Advanced Research Institute Inc $12,092
  • Vilo Research Group Inc $11,476
  • Regional Gastroenterology Associates of Lancaster LTD $11,422
  • Yale University $9,092
  • Hospital of Univ of Pennsylvania, PA $8,580
  • Baylor College of Medicine $7,866
  • Plains Clinical Research Center LLC $7,310
  • Texas Digestive Disease Cons PLLC $6,509
  • Weill Medical College of Cornell Universit $5,000
  • Gi Pros $4,112
  • Regents of the Univ of California $3,974
  • Clinical Research Institute Of $2,376
  • Carolinas Medical Center-Northeast, NC $2,227
  • Digestive Disease Specialists Inc $2,108
  • Gastroenterology Associates PA of Greenville $2,000
  • Tyler Research Institute LLC $1,701
  • The Trustees of Columbia University $861
  • Nola Research Works LLC $308
  • UCSF Langley Porter Psychiatric Hospital and Clinics, CA $241
  • Texas Digestive Disease Consultants PA $184
  • Cfagi LLC $133

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.